Pathstone Family Office’s Vaxart VXRT Stock Holding History

Pathstone Family Office’s Portfolio VXRT Stock Details VXRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,720	Closed	-$442K	–	1521
2022 Q4	$442K	Buy	+1,720	New	+$2.43K	﹤0.01%	1154

Other funds holding VXRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pathstone Family Office's VXRT Position: Q1 2023 in Review

Pathstone Family Office sold out of Vaxart (VXRT) in Q1 2023, closing a stake of 1,720 shares — an estimated $442K sold.

Pathstone Family Office first reported a position in VXRT in Q4 2022 and held it in 1 quarter. The position peaked at $442K in Q4 2022. 109 funds tracked by Wall St. Rank hold VXRT as of Q1 2023.

Pathstone Family Office reported no remaining Vaxart position as of Q1 2023 after selling out during the quarter.
Pathstone Family Office sold 1,720 Vaxart shares in Q1 2023, an estimated $442K.
Pathstone Family Office first reported a position in Vaxart in Q4 2022 and held it in 1 quarter.
Pathstone Family Office's Vaxart position peaked at $442K in Q4 2022.
109 funds tracked by Wall St. Rank held Vaxart as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.